Ardent Health unveils $50 million stock buyback initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy ARDT?
Share Repurchase Program: Ardent's board has authorized a share repurchase program of up to $50 million.
Funding and Financial Position: The program will be funded from existing cash resources, with Ardent maintaining a strong liquidity position of $609 million in cash.
Strategic Growth Opportunities: The share repurchase does not hinder Ardent's ability to pursue strategic growth opportunities, including mergers and acquisitions.
Leverage Ratio: As of the end of Q3 2025, Ardent's lease-adjusted net leverage stands at 2.5x.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ardent Health Securities Class Action Reminder
- Deadline for Claims: Investors must file lead plaintiff applications for the securities class action against Ardent Health by March 9, 2026, if they purchased the company's securities between July 18, 2024, and November 12, 2025, ensuring their right to participate in the lawsuit.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million decrease in Q3 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, which has led to a significant decline in market confidence regarding the company's financial health.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to a midpoint of $575 million, down approximately 9.6% from the previous $625 million, reflecting persistent industry-wide cost pressures and payer denials, which could negatively impact investor return expectations.
- Stock Price Plunge: Following the financial disclosures, Ardent's stock price plummeted from $14.05 to $9.30 per share, a nearly 34% drop, indicating severe market concerns about the company's future profitability and stability.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ardent Health, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by March 9, 2026.
- Significant Revenue Decline: Ardent reported a $43 million decrease in Q3 2025 revenue, primarily due to revised assessments of accounts receivable collectability following the transition to a new revenue accounting system, which raises concerns about the company's financial stability.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to between $530 million and $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials.
- Stock Price Plummet: Following the negative news, Ardent's stock price fell by $4.75, or 33.81%, closing at $9.30 per share on November 13, 2025, indicating significant market concerns regarding the company's financial health.
See More
Ardent Health Faces Securities Class Action Lawsuit
- Lawsuit Background: Ardent Health, Inc. (NYSE: ARDT) is facing a securities class action lawsuit for failing to disclose uncollectible accounts in a timely manner, with allegations that it used an improper 180-day reserve period, resulting in a 33% stock price drop.
- Financial Impact: The lawsuit highlights that Ardent Health failed to accurately reflect a massive $54 million increase in professional liability reserves in its financial reports, directly affecting the company's financial transparency and investor confidence.
- Investor Action: Hagens Berman law firm has notified investors and is encouraging those who purchased ARDT shares between July 18, 2024, and November 12, 2025, to contact them by March 9, 2026, to become lead plaintiffs and seek legal remedies.
- Compliance Risks: The case reveals that Ardent Health may have intentionally delayed recognizing losses during its early public company months to maintain an artificial earnings quality profile, potentially leading to broader compliance and reputational risks.
See More
Ardent Health Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a significant 33% stock drop on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health misrepresented its receivables by failing to accurately reflect its collection practices, leading to inflated accounts receivable during the reporting period, which undermines investor confidence.
- Stock Price Impact: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease and a $54 million increase in professional liability reserves, causing its stock price to plummet from $14.05 to $9.30, a decline exceeding 33%.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, and a favorable outcome could significantly impact Ardent Health's future financial standing.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health in the Middle District of Tennessee, representing investors who purchased securities between July 18, 2024, and November 12, 2025, raising serious concerns about the company's financial transparency.
- Financial Issues Exposed: The complaint alleges that Ardent Health reported inflated accounts receivable and delayed recognizing uncollectible losses, leading to investor worries about its financial health and potential impacts on future financing capabilities.
- Significant Stock Drop: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease for Q3 due to revised accounts receivable collectability, causing its stock price to plummet from $14.05 to $9.30, a nearly 34% drop, reflecting market disappointment in the company's financial status.
- Investor Rights Protection: Investors must apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating a focus on corporate governance and financial reporting, which may prompt the company to enhance its financial transparency and compliance.
See More
Ardent Health Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, that the deadline to apply as lead plaintiff is March 9, 2026, and failure to act may result in loss of claims.
- Fee Structure: Investors joining the Ardent Health class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, failing to accurately reflect their collectability, which led to investor losses following the revelation of these issues, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
Ardent Health Securities Class Action Reminder
- Deadline for Claims: Investors must file lead plaintiff applications for the securities class action against Ardent Health by March 9, 2026, if they purchased the company's securities between July 18, 2024, and November 12, 2025, ensuring their right to participate in the lawsuit.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million decrease in Q3 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, which has led to a significant decline in market confidence regarding the company's financial health.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to a midpoint of $575 million, down approximately 9.6% from the previous $625 million, reflecting persistent industry-wide cost pressures and payer denials, which could negatively impact investor return expectations.
- Stock Price Plunge: Following the financial disclosures, Ardent's stock price plummeted from $14.05 to $9.30 per share, a nearly 34% drop, indicating severe market concerns about the company's future profitability and stability.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ardent Health, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by March 9, 2026.
- Significant Revenue Decline: Ardent reported a $43 million decrease in Q3 2025 revenue, primarily due to revised assessments of accounts receivable collectability following the transition to a new revenue accounting system, which raises concerns about the company's financial stability.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to between $530 million and $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials.
- Stock Price Plummet: Following the negative news, Ardent's stock price fell by $4.75, or 33.81%, closing at $9.30 per share on November 13, 2025, indicating significant market concerns regarding the company's financial health.
See More
Ardent Health Faces Securities Class Action Lawsuit
- Lawsuit Background: Ardent Health, Inc. (NYSE: ARDT) is facing a securities class action lawsuit for failing to disclose uncollectible accounts in a timely manner, with allegations that it used an improper 180-day reserve period, resulting in a 33% stock price drop.
- Financial Impact: The lawsuit highlights that Ardent Health failed to accurately reflect a massive $54 million increase in professional liability reserves in its financial reports, directly affecting the company's financial transparency and investor confidence.
- Investor Action: Hagens Berman law firm has notified investors and is encouraging those who purchased ARDT shares between July 18, 2024, and November 12, 2025, to contact them by March 9, 2026, to become lead plaintiffs and seek legal remedies.
- Compliance Risks: The case reveals that Ardent Health may have intentionally delayed recognizing losses during its early public company months to maintain an artificial earnings quality profile, potentially leading to broader compliance and reputational risks.
See More
Ardent Health Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a significant 33% stock drop on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health misrepresented its receivables by failing to accurately reflect its collection practices, leading to inflated accounts receivable during the reporting period, which undermines investor confidence.
- Stock Price Impact: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease and a $54 million increase in professional liability reserves, causing its stock price to plummet from $14.05 to $9.30, a decline exceeding 33%.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, and a favorable outcome could significantly impact Ardent Health's future financial standing.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health in the Middle District of Tennessee, representing investors who purchased securities between July 18, 2024, and November 12, 2025, raising serious concerns about the company's financial transparency.
- Financial Issues Exposed: The complaint alleges that Ardent Health reported inflated accounts receivable and delayed recognizing uncollectible losses, leading to investor worries about its financial health and potential impacts on future financing capabilities.
- Significant Stock Drop: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease for Q3 due to revised accounts receivable collectability, causing its stock price to plummet from $14.05 to $9.30, a nearly 34% drop, reflecting market disappointment in the company's financial status.
- Investor Rights Protection: Investors must apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating a focus on corporate governance and financial reporting, which may prompt the company to enhance its financial transparency and compliance.
See More
Ardent Health Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, that the deadline to apply as lead plaintiff is March 9, 2026, and failure to act may result in loss of claims.
- Fee Structure: Investors joining the Ardent Health class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, failing to accurately reflect their collectability, which led to investor losses following the revelation of these issues, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
